NeoGenomics (NEO) – Globe Newswire
-
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
-
Press release Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery
-
Neo Performance Materials and Hudson Resources Advance the Greenland Sarfartoq Rare Earth Project After Receiving Government Approval for License Transfer
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Silvergate, NeoGenomics, Iris, and NewAge and Encourages Investors to Contact the Firm
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEO
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
-
Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022
-
Hudson Resources and Neo Performance Materials Sign Agreement on the Sarfartoq Rare Earth Element Project in Greenland
-
Bragar Eagel & Squire, P.C. Is Investigating TrueBlue, NeoGenomics, GoodRx, and Ebix and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Outset Medical, TrueBlue, Gap, and NeoGenomics and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Gap and NeoGenomics and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, CIRCOR, and NeoGenomics and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Agrify, Pegasystems, Unity Software, and NeoGenomics and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Barclays, CIRCOR, and NeoGenomics and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating CIRCOR, NeoGenomics, First High-School, and Enservco and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating NeoGenomics and First High-School and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating CIRCOR, NeoGenomics, Stryker, and Mullen and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Stronghold, CIRCOR, Barclays, and NeoGenomics and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Natera, Li-Cycle, Barclays, and NeoGenomics and Encourages Investors to Contact the Firm
-
Genetron Health Reports Third Quarter 2021 Unaudited Financial Results
-
Genetron Health Reports Third Quarter 2021 Unaudited Financial Results
-
Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Development
-
Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Development
-
Parexel and NeoGenomics Announce Strategic Collaboration in Precision Medicine to Improve Study Designs and Accelerate Patient Matching in Oncology Clinical Trials
-
Parexel and NeoGenomics Announce Strategic Collaboration in Precision Medicine to Improve Study Designs and Accelerate Patient Matching in Oncology Clinical Trials
-
Annual results for the year ended 31 March 2020
-
Annual results for the year ended 31 March 2020
-
Esteemed REE Industry Veteran Constantine Karayannopoulos to Keynote G&W and Miller Thomson Rare-Earth Elements and Critical Materials Supply Chains Seminar 2020
-
Sorrento Announces New Board Member
Back to NEO Stock Lookup
